Researcher
Kim De Keersmaecker
- Disciplines:Cancer biology
Affiliations
- Laboratory for Disease Mechanisms in Cancer (Division)
Responsible
From1 Oct 2016 → Today - Laboratory for Disease Mechanisms in Cancer (Division)
Member
From1 Oct 2014 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2013 → 30 Sep 2014 - Laboratory of Molecular Biology of Leukemia (VIB-KU Leuven) (Division)
Member
From1 Mar 2009 → 30 Sep 2015
Projects
1 - 10 of 42
- Raising the voice of silent mutations in cancerFrom1 Oct 2023 → TodayFunding: BOF - postdoctoral mandates
- Deregulated mRNA transcription and protein translation in the transformation of normal T-cells to malignant cells.From1 Jan 2023 → TodayFunding: BOF - iBOF
- Serine/glycine synthesis addiction in acute lymphoblastic leukemia and resulting therapeutic opportunitiesFrom4 Jul 2021 → TodayFunding: FWO fellowships
- Serine/glycine synthesis addiction in acute lymphoblastic leukemia and resulting therapeutic opportunitiesFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- VyCAP single cell isolation platform for high-quality single-cell analysisFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- Role of -1 programmed ribosomal frameshifting dysregulation on the JAK2 oncogeneFrom25 Jul 2020 → TodayFunding: FWO fellowships
- Silent mutations in cancerFrom1 May 2020 → TodayFunding: H2020 - Frontier Research (ERC)
- The role of NKX2-1 in T-cell acute lymphoblastic leukemia and NKX2-1 cooperation with the ribosomal RPL10 R98S and NOTCH1 mutations.From1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
- Role of PTEN dysregulation downstream of ribosomal protein RPL5/RPL11 lesions in cancer.From1 Jan 2020 → 31 Dec 2023Funding: FWO research project (including WEAVE projects)
- Fidelity of translation in healthy agingFrom26 Sep 2019 → 26 Sep 2023Funding: BOF - doctoral mandates
Publications
31 - 40 of 90
- Cancer Biogenesis in Ribosomopathies(2019)
Authors: Kim Kampen, Kim De Keersmaecker
- Ribosomal Lesions Promote Oncogenic Mutagenesis(2019)
Authors: Sergey Sulima, Kim Kampen, Stijn Vereecke, Daniele Pepe, Laura Fancello, Kim De Keersmaecker
Pages: 320 - 327 - Rise of the specialized onco-ribosomes.(2018)
Authors: Kim Kampen, Sergey Sulima, Kim De Keersmaecker
Pages: 35205 - 35206 - VEGFC Antibody Therapy Drives Differentiation of AML(2018)
Authors: Kim Kampen, Kim De Keersmaecker
Pages: 5940 - 5948 - Bloody Mysteries of Ribosomes(2018)
Authors: Kim De Keersmaecker
- The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL(2018)
Authors: Kim Kampen, Sergey Sulima, Benno Verbelen, Tiziana Girardi, Stijn Vereecke, Gianmarco Rinaldi, Anne Uyttebroeck, Jan Cools, David Cassiman, Sarah-Maria Fendt, et al.
Pages: 319 - 332 - Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia(2018)
Authors: Jolien De Bie, Sofie Demeyer, Ellen Geerdens, Heidi Segers, Michaël Broux, Kim De Keersmaecker, Lucienne Michaux, Peter Vandenberghe, Thierry Voet, Nancy Boeckx, et al.
Pages: 1358 - 1369 - EML1–ABL1 Is Activated by Coiled-Coil-Mediated Oligomerization and Induces T-Cell Acute Lymphoblastic Leukemia or Myeloproliferative Disease in a Mouse Bone Marrow Transplant Model(2018)
Authors: Kim De Keersmaecker, Marlies Vanden Bempt, Peter Vandenberghe, Jan Cools
- The T-cell leukemia associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling(2018)
Authors: Tiziana Girardi, Stijn Vereecke, Sergey Sulima, Laura Fancello, Ellen Geerdens, Carmen Vicente, Simon Bornschein, Jan Cools, Kim Kampen, Kim De Keersmaecker
Pages: 809 - 819 - The T-cell leukemia associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling(2018)
Authors: Tiziana Girardi, Stijn Vereecke, Sergey Sulima, Y Khan, Laura Fancello, JW Briggs, C Schwab, JO de Beeck, J Verbeeck, Jonathan Royaert, et al.
Pages: 809 - 819
Patents
1 - 3 of 3